Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
19 October 2016Website:
http://www.crisprtx.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:55:04 GMTDividend
Analysts recommendations
Institutional Ownership
CRSP Latest News
It won't be able to be profitable without hitting its targets for both of these figures.
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline.
This company might be worth far more than many realize.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.36, representing a -1.23% change from its previous close.
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.
The average of price targets set by Wall Street analysts indicates a potential upside of 67.5% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.
The markets this biotech is looking to enter could be extremely lucrative.
They won't remain southbound forever.
What type of business is CRISPR Therapeutics AG?
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
What sector is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG is in the Healthcare sector
What industry is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG is in the Biotechnology industry
What country is CRISPR Therapeutics AG from?
CRISPR Therapeutics AG is headquartered in Switzerland
When did CRISPR Therapeutics AG go public?
CRISPR Therapeutics AG initial public offering (IPO) was on 19 October 2016
What is CRISPR Therapeutics AG website?
https://www.crisprtx.com
Is CRISPR Therapeutics AG in the S&P 500?
No, CRISPR Therapeutics AG is not included in the S&P 500 index
Is CRISPR Therapeutics AG in the NASDAQ 100?
No, CRISPR Therapeutics AG is not included in the NASDAQ 100 index
Is CRISPR Therapeutics AG in the Dow Jones?
No, CRISPR Therapeutics AG is not included in the Dow Jones index
When was CRISPR Therapeutics AG the previous earnings report?
No data
When does CRISPR Therapeutics AG earnings report?
The next expected earnings date for CRISPR Therapeutics AG is 06 November 2024